Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Clin Lung Cancer. 2018 Sep;19(5):e811-e814. doi: 10.1016/j.cllc.2018.06.005. Epub 2018 Jul 3.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

Author information

1
Unit of Thoracic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: martina.imbimbo@istitutotumori.mi.it.
2
Unit of Thoracic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3
Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
4
Rare Tumors Reference Center, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
5
Department of Medical Oncology 2, Istituto Oncologico Veneto IRCCS Padova, Padua, Italy.
6
Division of General Pathology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
7
Oncology Clinic, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy.
8
Department of Medical Oncology, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy.
9
Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
10
Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy.
11
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
12
Laboratory of Methodology for Biomedical Research, IRCCS Mario Negri Institute for Pharmacological Research, Milan, Italy.

Abstract

Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The association of chemotherapy and antiangiogenic agents in the first-line setting has never been investigated in this very rare cancer. However, preclinical and clinical evidence has suggested that inhibition of angiogenesis could be beneficial. The RELEVENT trial is a multicenter, open-label, single-arm, phase II study aimed at investigating the activity and safety of ramucirumab combined with paclitaxel and carboplatin in chemotherapy-naive patients affected by thymic carcinoma or B3 thymoma with area of carcinoma. The primary endpoint of the trial is the overall response rate. Progression-free survival, overall survival, and safety are secondary endpoints. Patient-reported outcomes will be collected at each visit. The mutational status of a subset of genes, polymorphisms, and selected micro-RNA expression will be evaluated.

KEYWORDS:

Advanced; Biologic therapy; First line; TC; TET

PMID:
30033090
DOI:
10.1016/j.cllc.2018.06.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center